Akebia Therapeutics Inc.
AKBA
Market Cap$832.56M
Close$
$-2.19
172.4% downside
Current Fair Value
172.4% downsideOvervalued by 172.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $832.56 Million |
|---|---|
| Enterprise Value | $754.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.33 |
| Beta | 0.96 |
| Outstanding Shares | 262,565,500 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -22.6 |
|---|---|
| PEG | 21.97 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.74 |
| Enterprise Value to EBIT | -96.23 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 2.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler